# Exploratory Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Tumor Neoantigen-pulsed Autologous Dendritic Cell Injection (YS247, Beijing YSCell Biotech Co., Ltd. [Abbreviated as YS])in Patients With Recurrent or Progressive Glioblastoma

> clinical trial · VERIFIED · 2026-07-01

Status: NOT_YET_RECRUITING · Sponsor: Huanhu Hospital Affiliated to Tianjin Medical University · Condition: Glioblastoma

- Company: Huanhu Hospital Affiliated to Tianjin Medical University
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07678138

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.